Skip to content

Study · Randomized controlled trial · 2008

2 results

Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy.

Peyrot M, Rubin RR, Polonsky WH

Diabetes technology & therapeutics1 Dec 2008Cited by 17 (Europe PMC)

PMID19049375 (opens in a new tab)DOI10.1089/dia.2008.0031 (opens in a new tab)PepBankPUB-19049375
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes above median baseline distress, pramlintide was associated with reduced total diabetes distress.

    In plain wordsIn patients with higher baseline distress, pramlintide use was linked to lower diabetes distress.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseTotal diabetes distress
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Pramlintide use was associated with a significant reduction in total DDS and RD, but only among those above the median of distress at baseline.
    2 context sentences
    Summary · context
    In a 16-week, double-blind, placebo-controlled study 211 patients using insulin glargine with or without oral antidiabetes agents were randomized to addition of pramlintide or placebo.
    Summary · context
    Hierarchical, stepwise multiple regression was used to assess the association of clinical outcomes and during-trial hypoglycemia with DDS score changes during the study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes above median baseline distress, pramlintide was associated with reduced regimen distress.

    In plain wordsIn patients with higher baseline distress, pramlintide use was linked to lower distress about treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseRegimen distress
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Pramlintide use was associated with a significant reduction in total DDS and RD, but only among those above the median of distress at baseline.
    2 context sentences
    Summary · context
    In a 16-week, double-blind, placebo-controlled study 211 patients using insulin glargine with or without oral antidiabetes agents were randomized to addition of pramlintide or placebo.
    Summary · context
    Hierarchical, stepwise multiple regression was used to assess the association of clinical outcomes and during-trial hypoglycemia with DDS score changes during the study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00240253

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

AstraZenecan = 200Oct 2005 to Jun 2006

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 31 Mar 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.